A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
← catalyst calendarNCT04042844 · readout ≤ 134 d
Sponsored by BioRestorative Therapies (industry) · BRTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
99estimated
Sites
19
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-30 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-08-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lumbar Disc Disease
Interventions
- Biological: BRTX-100
- Drug: Saline
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety Measures
measured Baseline through Week 104 / Early Termination
Primary Efficacy Measures
measured Baseline through Week 52
Permalink · BRTX's whole pipeline · Catalyst calendar · Every registered study · What changed